Broker Ratings

Repligen Corporation – Consensus ‘buy’ rating and 9.2% Upside Potential

Repligen Corporation which can be found using ticker (RGEN) now have 13 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $210.00 and $148.00 and has a mean target at $171.38. Given that the stocks previous close was at $156.90 this would indicate that there is a potential upside of 9.2%. Also worth taking note is the 50 day moving average now sits at $149.68 and the 200 moving average now moves to $161.14. The company has a market cap of 8.90B. The current share price for the company is: $159.49 USD

The potential market cap would be $9,726,438,295 based on the market consensus.

The company has a dividend yield of 5.38%. Other points of data to note are a P/E ratio of 78.57, revenue per share of $12.04 and a 2.08% return on assets.

Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company’s bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins. The Filtration products are used in process development and process scale production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all monoclonal antibody (mAb) based drugs on the market.

Share on:
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

    Repligen Corporation (RGEN) Stock Analysis: Exploring a Promising 18.17% Upside Potential

    Repligen Corporation (NASDAQ: RGEN), a prominent player in the healthcare sector, is catching the eye of investors with its robust 18.17% potential upside, as indicated by the average analyst target

    Repligen Corporation (RGEN) Stock Analysis: An Investor’s Guide to a 23.4% Potential Upside

    Repligen Corporation (NASDAQ: RGEN) is making waves in the healthcare sector, particularly within the medical instruments and supplies industry. With a market capitalization of $8.17 billion, this Massachusetts-based life sciences

    Repligen Corporation (RGEN) Stock Analysis: Exploring a 19.75% Potential Upside with Robust Revenue Growth

    Repligen Corporation (NASDAQ: RGEN), a distinguished player in the healthcare sector, particularly within the medical instruments and supplies industry, stands out with its innovative bioprocessing technologies. With a market capitalization

    Repligen Corporation (RGEN) Stock Analysis: Exploring a 42.65% Potential Upside in the Bioprocessing Sector

    Repligen Corporation (NASDAQ: RGEN), a leading player in the healthcare sector specializing in medical instruments and supplies, presents an intriguing proposition for investors keen on the life sciences domain. With

    Repligen Corporation (RGEN) Stock Analysis: 42.65% Potential Upside Ignites Investor Interest

    Repligen Corporation (NASDAQ: RGEN), a prominent player in the healthcare sector, particularly in the medical instruments and supplies industry, is capturing investor attention with a compelling potential upside of 42.65%.

    Repligen Corporation (RGEN) Stock Analysis: Uncovering a 46.54% Potential Upside in the Booming Bioprocessing Sector

    For investors looking to tap into the burgeoning healthcare sector, Repligen Corporation (NASDAQ: RGEN) stands out as a compelling opportunity. With a market capitalization of $6.88 billion, Repligen is a

      Search

      Search